In our previous blog post, we reported that our antibody CR3022 (Ab01680) binds to novel coronavirus variants. Further data shows the binding capabilities of many of our other popular anti-SARS-CoV-2 antibodies.
CR3022 (Ab01680) has distinguished itself as a formidable binder, able to recognize virtually all tested SARS-CoV-2 mutant variants (Younger et al., 2021). To expand on these findings, we have further tested CR3022 as well as other coronavirus antibodies with three of the most prominent and troubling Spike mutants: B.1.1.7 (UK variant), B.1.351 (501Y.V2; South African variant) and B1.1.24 / P.1 (Brazilian variant). We are pleased to report that most of the tested clones show excellent cross-reactivity between spike mutants, however some clones do not bind singular mutants. This should be taken into consideration when selecting clones or clone-combinations.
Our anti-coronavirus clones CV1 (Ab02018), CV30 (Ab02019), Sb#15 (Ab02013), EY6A (Ab02057) and CR3022 (Ab01680) are available in our catalog in a wide variety of engineered formats, designed to open up new experimental possibilities for in vitro and in vivo use. Some of the formats include:
- Human IgG1, IgG2, IgG3, IgG4, IgA, IgM and IgE for use in neutralization assays and as serological controls
- Rabbit, mouse, cat and ferret formats for detection applications, co-labeling studies and animal model research
- Human and mouse Fab and Fab2 formats with His-tags, for applications where antibody fragments are desirable and for site-specific functionalization
- Human IgG1 and mouse IgG2b Fc Silent™ formats, which are aimed at discerning Fc-dependent and Fc-independent effector functions and facilitating research into the role of antibody-dependent enhancement (ADE)
Learn more about each antibody format here or contact us if you are looking for the these clones in a different format. You can also find our full collection of anti-coronavirus antibodies on our website here.
Figure 1. ELISA using CV1 (Ab02018) with the UK and South African mutant Spike proteins. The plate was coated with the mutant Spike proteins (The Native Antigen Company) at 2.5 µg/ml. Ab02018 was conjugated to HRP and titrated on a 3-fold serial dilution starting at 1,000 ng/ml. View the rest of the figures here.
Review the binding abilities of the selected coronavirus antibodies below in the table and view all of the graphs representing the binding data here.
|Clone ID||Clone Name||Antigen||B.1.1.7 (UK variant)||B.1.351 (501Y.V2; South African variant)||B1.1.24 / P.1 (Brazilian variant)|
|Ab01680||CR3022||COVID-19 & SARS-CoV S glycoprotein||✓||✓||✓|
|Ab02019||CV30||Spike Protein (RBD)||✓||✓||✓|
|Ab02013||Sb#15||Spike protein (RBD)||✓||No binding observed||No binding observed|
|Ab02061||Ty1||Spike protein||✓||No binding observed||Not yet determined|
ACE2-IgG Fc (LALA)-Fusion Protein
Table 1. Chosen anti-coronavirus antibodies and their binding to three major SARS-CoV-2 Spike variants assessed by ELISA. ✓ = binding.
AACC Annual Meeting – Booth #3459
26-30th September 2021